Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc. DESIGN AND METHODS: Data from 1039 adults naive to l...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270504/
https://www.ncbi.nlm.nih.gov/pubmed/33730748
http://dx.doi.org/10.1097/QAD.0000000000002883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270504/
https://www.ncbi.nlm.nih.gov/pubmed/33730748
http://dx.doi.org/10.1097/QAD.0000000000002883

Ejemplares similares